Eptinezumab Real-World Effectiveness in Chronic Migraine: Increased Dosing
Real-world analysis of eptinezumab in chronic migraine shows increased dosing frequency or amount improved outcomes in patients with insufficient initial response.
Quick Facts
What This Study Found
Real-world analysis of eptinezumab in chronic migraine shows increased dosing frequency or amount improved outcomes in patients with insufficient initial response.
Key Numbers
Three subgroups analyzed: psychiatric comorbidities, prior subcutaneous anti-CGRP treatment, and migraine-associated brain fog. Outcome: increase in good days.
How They Did This
In publication.
Why This Research Matters
Relevant to peptide therapeutics.
The Bigger Picture
Advances peptide evidence.
What This Study Doesn't Tell Us
In publication.
Questions This Raises
- ?Long-term implications?
- ?Evidence comparison?
- ?Next steps?
Trust & Context
- Key Stat:
- Key finding Real-world analysis of eptinezumab in chronic migraine shows increased dosing frequency or amount im
- Evidence Grade:
- Based on design.
- Study Age:
- Published in 2025.
- Original Title:
- Real-world effectiveness of eptinezumab in chronic migraine-increase in good days in three subgroups: psychiatric comorbidities, prior subcutaneous anti-calcitonin gene-related peptide therapy, and migraine-associated brain fog.
- Published In:
- The journal of headache and pain, 26(1), 274 (2025)
- Authors:
- Argoff, Charles, Khan, Fawad A, Herzog, Steven P, Smith, Ryan M, Soni-Brahmbhatt, Seema, Asher, Divya, Awad, Susanne F, Grossman, S Wald, Patel, Foram, Buse, Dawn C
- Database ID:
- RPEP-09972
Evidence Hierarchy
Frequently Asked Questions
What does this mean?
Real-world analysis of eptinezumab in chronic migraine shows increased dosing frequency or amount improved outcomes in patients with insufficient initial response.
How reliable?
Consult publication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09972APA
Argoff, Charles; Khan, Fawad A; Herzog, Steven P; Smith, Ryan M; Soni-Brahmbhatt, Seema; Asher, Divya; Awad, Susanne F; Grossman, S Wald; Patel, Foram; Buse, Dawn C. (2025). Real-world effectiveness of eptinezumab in chronic migraine-increase in good days in three subgroups: psychiatric comorbidities, prior subcutaneous anti-calcitonin gene-related peptide therapy, and migraine-associated brain fog.. The journal of headache and pain, 26(1), 274. https://doi.org/10.1186/s10194-025-02165-2
MLA
Argoff, Charles, et al. "Real-world effectiveness of eptinezumab in chronic migraine-increase in good days in three subgroups: psychiatric comorbidities, prior subcutaneous anti-calcitonin gene-related peptide therapy, and migraine-associated brain fog.." The journal of headache and pain, 2025. https://doi.org/10.1186/s10194-025-02165-2
RethinkPeptides
RethinkPeptides Research Database. "Real-world effectiveness of eptinezumab in chronic migraine-..." RPEP-09972. Retrieved from https://rethinkpeptides.com/research/argoff-2025-realworld-effectiveness-of-eptinezumab
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.